The emergence of large number of antimicrobial-resistant organisms has given alarming magnitude. Nature is historically the source of drugs, and microorganisms have provided a significant number of antibiotic compounds, which are used every day in the treatment of many infectious diseases. However, the introduction to the pharmaceutical market of new therapeutic molecules has largely decreased during the last two decades. In this review, antibiotics from the genus Micromonospora are recognized as potential biofactory for new antibiotic production. The Micromonospora has been deeply studied and more than 100 antibiotics isolated from different Micromonospora strains. In addition, comprehensive information about the recent development in the field of analytical, biological and bioinformatics screening tools, which recently used in the discovery of new therapeutic compounds, are provided. It is widely believed that reviving old antibiotics produced by Micromonospora is possible and the study of this genus is still interesting for novel bioactive molecules discovery.